Histone deacetylase inhibitors: novel agents in cancer treatment.
Histone deacetylase inhibitors (HDAC-Is) are agents that have demonstrated anticancer activity in vivo and in vitro, leading to clinical trials evaluating their efficacy in multiple cancer types. Only two HDAC-Is are currently approved by the U.S. Food and Drug Administration, vorinostat and romidepsin, both with indications for cutaneous T-cell lymphoma. Romidepsin has an additional approval in peripheral T-cell lymphoma. Promising clinical trial results in other cancer types will likely lead to expanded use of these and other HDAC-Is. To provide care for patients receiving these agents, oncology nurses should be knowledgeable about the emerging role of HDAC-Is. This article reviews the mechanism of action of HDAC-Is, currently approved therapies, and nursing management of cutaneous T-cell lymphoma.
St. Agnes Cancer Institute, Baltimore, MD, USA. ericaglass@hotmail.com
Erica
E
Glass
Pamela Hallquist
PH
Viale
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D047630:Depsipeptides / Q000627:therapeutic use*; D004509:Education, Nursing, Continuing; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000451:nursing; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000451:nursing; D014481:United States; D014486:United States Food and Drug Administration; D000077337:Vorinostat
D000970:Antineoplastic Agents; D047630:Depsipeptides; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D000077337:Vorinostat; C087123:romidepsin